Telavancin is a semisynthetic lipoglycopeptide antibacterial API structurally derived from vancomycin. The pharmaceutical substance is used as Telavancin Hydrochloride and is designed primarily for activity against Gram-positive bacterial pathogens. Telavancin combines inhibition of bacterial cell-wall synthesis with disruption of bacterial membrane integrity.
Telavancin is identified by CAS No. 372151-71-8 for the parent telavancin substance. The hydrochloride form is separately registered as CAS No. 560130-42-9 and FDA GSRS UNII 0701472ZG0.
The commercially relevant pharmaceutical form is Telavancin Hydrochloride. FDA regulatory documentation describes the drug substance as a hydrochloride material with variable hydrochloride association, represented as C80H106Cl2N11O27P·xHCl, where x = 1–3. FDA's original review reports a free-base molecular weight of approximately 1755.63 g/mol.
PubChem separately represents the 1:1 hydrochloride structure as C80H107Cl3N11O27P, with a calculated molecular weight of 1792.1 g/mol. Because the regulatory material describes variable hydrochloride association, the exact salt stoichiometry should be confirmed against the applicable API specification rather than assuming a single molecular-weight value for every commercial batch.
Telavancin is a semisynthetic derivative of vancomycin containing a lipophilic decylaminoethyl substituent and a phosphonomethylaminomethyl modification. These structural changes contribute to its antibacterial activity and pharmacokinetic characteristics.
The parent telavancin record has molecular formula C80H106Cl2N11O27P and molecular weight 1755.6 g/mol. It contains numerous stereogenic centers characteristic of its glycopeptide structure.
Telavancin has a dual antibacterial mechanism. Similar to vancomycin, it binds to the D-alanyl-D-alanine terminus of bacterial cell-wall precursors and interferes with peptidoglycan synthesis. In addition, its lipophilic side chain interacts with bacterial membranes and contributes to membrane depolarization and disruption of membrane barrier function.
This dual mechanism contributes to the bactericidal activity of telavancin against susceptible Gram-positive organisms, including strains of Staphylococcus aureus.
Telavancin hydrochloride is an antibacterial API used in injectable pharmaceutical products.
Historically, U.S. telavancin products have been indicated for:
The historical Vibativ presentations included 250 mg and 750 mg telavancin per vial for intravenous administration.
Telavancin is a complex glycopeptide API and requires a substantially more sophisticated analytical control strategy than conventional small-molecule APIs. Regulatory assessment includes characterization and control of related substances, degradation products and other critical quality attributes. EMA's assessment notes that toxicology data were used to establish limits for related substances in drug-substance and drug-product specifications.
Because telavancin is a complex semisynthetic glycopeptide, conventional CMS fields such as pH of a 1% solution, specific rotation, melting point and simple small-molecule impurity limits should not be populated with invented numbers unless supported by the actual API specification.
Telavancin is manufactured as a semisynthetic derivative of vancomycin. Public regulatory information describes a process involving chemical modification of vancomycin followed by purification and isolation of the final active substance.
The manufacturing process requires control of starting-material quality, reaction conditions, purification, related substances, residual process materials and the final physicochemical characteristics of the glycopeptide API.
| Property | Value |
|---|---|
| Product Name | Telavancin Hydrochloride |
| API Class | Lipoglycopeptide Antibacterial |
| Parent Telavancin CAS | 372151-71-8 |
| Telavancin Hydrochloride CAS | 560130-42-9 |
| FDA UNII – Parent | XK134822Z0 |
| FDA UNII – Hydrochloride | 0701472ZG0 |
| Parent Molecular Formula | C80H106Cl2N11O27P |
| Parent Molecular Weight | 1755.6 g/mol |
| 1:1 HCl Formula Representation | C80H107Cl3N11O27P |
| 1:1 HCl Molecular Weight | 1792.1 g/mol |
| Development Codes | TD-6424, SPT3104, CD4, AMI-6424 |
| Physical Description | Off-white to slightly colored amorphous powder |
| Water Solubility | Slightly soluble |
| Therapeutic Class | Lipoglycopeptide antibacterial |
Telavancin hydrochloride API should be packaged in suitable pharmaceutical-grade, well-closed containers that protect the material from moisture and environmental contamination. Exact storage conditions should be established according to validated stability data and the applicable drug-substance specification.
Because telavancin is a complex glycopeptide and the hydrochloride material can exhibit variable hydrochloride association, packaging and storage should be controlled through the registered manufacturing and stability program.
Pharmaceutical-grade Telavancin Hydrochloride API documentation may include:
Telavancin Hydrochloride is a complex lipoglycopeptide API requiring specialized manufacturing and analytical controls. Quality management should focus on molecular identity, assay/potency, related substances, degradation products, salt form, residual process materials and microbiological quality as applicable.
For pharmaceutical development and commercial manufacturing, the API specification should be established specifically for the Telavancin Hydrochloride form and should not be substituted with generic vancomycin or conventional small-molecule API specifications.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |